Actinium Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Actinium Pharmaceuticals
ATNM Stock  USD 1.11  0.01  0.89%   
Actinium Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Actinium Pharmaceuticals' valuation are provided below:
Gross Profit
90 K
Market Capitalization
34.6 M
Enterprise Value Revenue
1.7 K
Revenue
90 K
Earnings Share
(1.11)
There are over one hundred nineteen available fundamental signals for Actinium Pharmaceuticals, which can be analyzed over time and compared to other ratios. Self-guided Investors are advised to validate Actinium Pharmaceuticals' prevailing fundamentals against the trend between 2010 and 2026 to make sure the company can sustain itself down the road.

Actinium Pharmaceuticals Total Revenue

81,000

Check Actinium Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Actinium Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 1.3 M, Selling General Administrative of 14.6 M or Other Operating Expenses of 50.9 M, as well as many indicators such as Price To Sales Ratio of 1.6 K, Dividend Yield of 0.0 or PTB Ratio of 1.09. Actinium financial statements analysis is a perfect complement when working with Actinium Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Actinium Stock
Check out the analysis of Actinium Pharmaceuticals Correlation against competitors.
To learn how to invest in Actinium Stock, please use our How to Invest in Actinium Pharmaceuticals guide.

Actinium Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets92.9 M88.4 M42 M
Slightly volatile
Short and Long Term Debt Total1.9 M1.8 M836.5 K
Slightly volatile
Total Current Liabilities5 M9.4 M5.9 M
Slightly volatile
Accounts Payable9.1 M8.7 M4.6 M
Slightly volatile
Cash88 M83.8 M39.8 M
Slightly volatile
Cash And Short Term Investments88 M83.8 M39.8 M
Slightly volatile
Common Stock Total Equity24 K25.3 K59.9 K
Slightly volatile
Common Stock Shares Outstanding36.3 M34.6 M11.8 M
Slightly volatile
Liabilities And Stockholders Equity92.9 M88.4 M42 M
Slightly volatile
Other Stockholder Equity493.3 M469.8 M226.8 M
Slightly volatile
Total Liabilities53.3 M50.8 M17.7 M
Slightly volatile
Total Current Assets90 M85.7 M40.8 M
Slightly volatile
Common Stock53 K27.9 K62.9 K
Slightly volatile
Net Receivables190.3 K214.1 K233.6 K
Slightly volatile
Other Current Assets1.2 M1.8 M1.1 M
Slightly volatile
Short Term Debt364.3 K667 K340.7 K
Slightly volatile
Property Plant And Equipment Net2.5 M2.4 M946.9 K
Slightly volatile
Non Current Assets Total2.9 M2.8 M1.2 M
Slightly volatile
Property Plant And Equipment Gross3.6 M3.4 M1.2 M
Slightly volatile
Property Plant Equipment3.6 M3.4 M1.1 M
Slightly volatile
Capital Surpluse201.8 M378.7 M200.8 M
Slightly volatile
Other Assets1.091.15197.5 K
Pretty Stable
Short Term Investments29.8 K40.2 K28 K
Slightly volatile
Long Term Investments39.9 K44.9 K49 K
Slightly volatile
Net Invested Capital41.1 M37.7 M27.9 M
Slightly volatile
Net Working Capital54.4 M76.3 M36.4 M
Slightly volatile
Long Term Debt Total90.4 K173.6 K75.9 K
Slightly volatile
Capital Lease Obligations1.3 M1.8 M682.8 K
Slightly volatile
Capital Stock46.3 K27.9 K82.7 K
Slightly volatile
Non Current Liabilities Other2.6 K2.7 K420.7 K
Slightly volatile
Other Liabilities28 M31.5 M34.4 M
Slightly volatile

Actinium Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative14.6 M13.9 M8.3 M
Slightly volatile
Other Operating Expenses50.9 M48.4 M25.8 M
Slightly volatile
Total Operating Expenses49.9 M47.5 M25.6 M
Slightly volatile
Depreciation And Amortization979.3 K932.6 K346 K
Slightly volatile
Research Development19.1 M34.6 M16.9 M
Slightly volatile
Interest Income4.7 M4.5 M2.5 M
Pretty Stable
Reconciled Depreciation517 K932.6 K329.5 K
Slightly volatile

Actinium Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
End Period Cash Flow88.4 M84.2 M40 M
Slightly volatile
Begin Period Cash Flow93 M88.5 M36.5 M
Slightly volatile
Stock Based Compensation2.6 M4.8 M3.2 M
Pretty Stable
Depreciation979.3 K932.6 K346 K
Slightly volatile
Change To Account Receivables187.2 K210.6 K229.9 K
Slightly volatile
Sale Purchase Of Stock33.4 M31.8 M19.8 M
Slightly volatile
Change To Netincome1.9 M2.5 M2.1 M
Pretty Stable
Issuance Of Capital Stock24.6 M26.3 M23.7 M
Slightly volatile
Dividends Paid9089001.1 K
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.6 K1.5 K468
Slightly volatile
Dividend Yield0.00.00.0
Slightly volatile
Average Payables1.3 M1.2 M1.1 M
Slightly volatile
Stock Based Compensation To Revenue44.8242.6911.9328
Slightly volatile
Capex To Depreciation0.01480.01561.915
Slightly volatile
EV To Sales707673206
Slightly volatile
Payables Turnover0.04980.09640.0533
Slightly volatile
Sales General And Administrative To Revenue15614846.1326
Slightly volatile
Research And Ddevelopement To Revenue451430120
Slightly volatile
Capex To Revenue1.791.70.5305
Slightly volatile
Cash Per Share2.652.7914.0072
Slightly volatile
Days Payables Outstanding3.7 K3.9 K14.1 K
Slightly volatile
Current Ratio8.648.235.4492
Slightly volatile
Capex Per Share4.0E-44.0E-40.0327
Slightly volatile
Revenue Per Share0.00330.00350.0425
Slightly volatile
Interest Debt Per Share0.05720.06022.361
Slightly volatile
Debt To Assets0.02230.02351.8555
Slightly volatile
Days Of Payables Outstanding3.7 K3.9 K14.1 K
Slightly volatile
Quick Ratio8.648.235.4492
Slightly volatile
Cash Ratio8.468.055.2972
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.11.151.0152
Slightly volatile
Fixed Asset Turnover0.03080.03251.2913
Slightly volatile
Debt Ratio0.02230.02351.8555
Slightly volatile
Price Sales Ratio1.6 K1.5 K468
Slightly volatile
Asset Turnover0.00110.00110.0108
Slightly volatile
Gross Profit Margin0.430.490.5323
Slightly volatile

Actinium Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap118.1 M145.1 M151.3 M
Pretty Stable
Enterprise Value113.4 M139.3 M145.3 M
Pretty Stable

Actinium Fundamental Market Drivers

Forward Price Earnings6.8399
Cash And Short Term Investments72.9 M

Actinium Upcoming Events

1st of April 2024
Upcoming Quarterly Report
View
20th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
1st of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Actinium Pharmaceuticals Financial Statements

Actinium Pharmaceuticals investors utilize fundamental indicators, such as revenue or net income, to predict how Actinium Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue40.2 M42.3 M
Cost Of Revenue932.6 K979.3 K
Stock Based Compensation To Revenue 42.69  44.82 
Sales General And Administrative To Revenue 148.12  155.53 
Research And Ddevelopement To Revenue 429.67  451.15 
Capex To Revenue 1.70  1.79 
Ebit Per Revenue(737.14)(700.28)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether Actinium Pharmaceuticals is a strong investment it is important to analyze Actinium Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Actinium Pharmaceuticals' future performance. For an informed investment choice regarding Actinium Stock, refer to the following important reports:
How To Invest In Actinium
Details
Is Actinium Stock a good investment?
Details
What is Actinium Pharmaceuticals' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Actinium Pharmaceuticals Correlation against competitors.
To learn how to invest in Actinium Stock, please use our How to Invest in Actinium Pharmaceuticals guide.
You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Will Biotechnology sector continue expanding? Could Actinium diversify its offerings? Factors like these will boost the valuation of Actinium Pharmaceuticals. If investors know Actinium will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Actinium Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(1.11)
Revenue Per Share
0.003
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.34)
Return On Equity
(1.33)
Understanding Actinium Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects Actinium's accounting equity. The concept of intrinsic value - what Actinium Pharmaceuticals' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Actinium Pharmaceuticals' price substantially above or below its fundamental value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Understanding that Actinium Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Actinium Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Actinium Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY